KR20240137027A - 항인간 cxcl1 항체 - Google Patents

항인간 cxcl1 항체 Download PDF

Info

Publication number
KR20240137027A
KR20240137027A KR1020247027221A KR20247027221A KR20240137027A KR 20240137027 A KR20240137027 A KR 20240137027A KR 1020247027221 A KR1020247027221 A KR 1020247027221A KR 20247027221 A KR20247027221 A KR 20247027221A KR 20240137027 A KR20240137027 A KR 20240137027A
Authority
KR
South Korea
Prior art keywords
amino acid
human
antibody
cancer
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027221A
Other languages
English (en)
Korean (ko)
Inventor
마사카즈 야시로
유리에 야마모토
아키코 요시오카
고지 나카무라
히로유키 야나이
도시카즈 이노우에
Original Assignee
치오메 바이오사이언스 가부시키가이샤
코우리츠 다이가꾸 호우진 오사카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치오메 바이오사이언스 가부시키가이샤, 코우리츠 다이가꾸 호우진 오사카 filed Critical 치오메 바이오사이언스 가부시키가이샤
Publication of KR20240137027A publication Critical patent/KR20240137027A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247027221A 2022-01-27 2023-01-26 항인간 cxcl1 항체 Pending KR20240137027A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2022-011107 2022-01-27
JP2022011107 2022-01-27
PCT/JP2023/002533 WO2023145844A1 (ja) 2022-01-27 2023-01-26 抗ヒトｃｘｃｌ１抗体

Publications (1)

Publication Number Publication Date
KR20240137027A true KR20240137027A (ko) 2024-09-19

Family

ID=87471580

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247027221A Pending KR20240137027A (ko) 2022-01-27 2023-01-26 항인간 cxcl1 항체

Country Status (10)

Country Link
US (1) US20250154240A1 (https=)
EP (1) EP4471057A4 (https=)
JP (1) JPWO2023145844A1 (https=)
KR (1) KR20240137027A (https=)
CN (1) CN118591554A (https=)
AU (1) AU2023213334A1 (https=)
CA (1) CA3249959A1 (https=)
IL (1) IL314512A (https=)
TW (1) TW202342528A (https=)
WO (1) WO2023145844A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060413A1 (en) * 2024-09-16 2026-03-19 Calgent Biotechnology Co., Ltd. Single chain antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP2997042B1 (en) * 2013-05-17 2019-08-07 Centre National de la Recherche Scientifique (CNRS) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
US20170058029A1 (en) 2014-05-02 2017-03-02 Chiome Bioscience Inc. Human antibody-producing cell
JP6932365B2 (ja) * 2015-05-14 2021-09-08 公立大学法人大阪 スキルス性胃癌の治療剤、及び胃癌の予後の予測方法
US11292832B2 (en) * 2019-01-28 2022-04-05 Charles J. Rosser Compositions and methods for treatment of diseases involving CXCL1 function
JP7471156B2 (ja) 2020-06-29 2024-04-19 ギガフォトン株式会社 極端紫外光集光ミラー及び電子デバイスの製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Augustin Le Naour et.al., J. Mol. Biol., Vol.12 (3), pp.202-2015, 2020
Hiroaki Kasashima et. Al., Am. J. Pathol., Vol.186, No.11, November 2016
Krishna Mohan Sepuru et.al., J.Biol Chem. 2016 Feb 19 ; 291 (8) : 4247-55
Lillian Sun et.al., JCI Insight, 2019 Apr 4 ; 4 (7)

Also Published As

Publication number Publication date
AU2023213334A1 (en) 2024-09-05
IL314512A (en) 2024-09-01
EP4471057A1 (en) 2024-12-04
WO2023145844A1 (ja) 2023-08-03
JPWO2023145844A1 (https=) 2023-08-03
CN118591554A (zh) 2024-09-03
EP4471057A4 (en) 2026-03-04
US20250154240A1 (en) 2025-05-15
TW202342528A (zh) 2023-11-01
CA3249959A1 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
US11498972B2 (en) Anti-OX40 antibody and use thereof
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
AU2011255870B2 (en) Anti-human TROP-2 antibody having antitumor activity in vivo
US8841424B2 (en) Humanized AXL antibodies
CA3048578A1 (en) Anti-cd47 antibodies and uses thereof
TW202144417A (zh) Ｐｖｒｉｇ結合蛋白及其醫藥用途
EA037397B1 (ru) Гуманизированные антитела к рецептору ccr7
KR20180054492A (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
US20190276557A1 (en) Antibody binding to carbonic anhydrase and use thereof
EP2270053A1 (en) Humanized AXL antibodies
KR20240137027A (ko) 항인간 cxcl1 항체
JP2021530250A (ja) Ｓｍｏタンパク質の特異的エピトープ、これを認知する抗体及びこれを含む組成物
TW202340250A (zh) 標靶ｃｄ２５的抗體及其製備方法和應用
JP7643727B2 (ja) 抗－ｆｇｆ１９抗体
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
KR20250001497A (ko) 항-cxcr2 항체 및 이의 용도
HK40085179A (en) Antibody molecules to c5ar1 and uses thereof
EA046377B1 (ru) Антитела к fgf19
BR112020006860A2 (pt) composição para depleção de células t citotóxicas
NZ623464B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
NZ716839B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
NZ716839A (en) Anti-human trop-2 antibody having an antitumor activity in vivo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000